Which company developed and marketed teclistamab?

Teclistamab is an innovative bispecific T cell-linked antibody drug developed by Janssen Pharmaceuticals, a subsidiary of the world-renowned pharmaceutical company Johnson & Johnson. The drug is designed to treat relapsed or refractory multiple myeloma (RRMM) and targets CD3 and BCMA (B cell maturation antigen) opens a novel immunotherapy path by "guiding" the patient's own T cells to attack myeloma cells.

In 2022, teritusumab received accelerated approval in Europe and the United States for the treatment of multiple myeloma patients after multiple treatment failures. It became the first BCMABCMA×CD3 bispecific antibody drug approved by the FDA, representing an important breakthrough in dual-antibody therapy from theory to clinical practice. Compared with CAR-T cell therapy, teritusumab can be directly injected subcutaneously, has a short preparation cycle and is more convenient to use, so it has quickly gained clinical approval in the European and American markets.

Multiple myeloma is a malignant hematological tumor that is difficult to cure. Relapse and drug resistance are the biggest challenges in its treatment. Teritusumab is particularly indicated for patients who have failed at least four therapies, such as proteasome inhibitors, immunomodulators, and anti-CD38 antibodies. Its efficacy has been confirmed in international key clinical studies such as MajesTEC-1, showing a high remission rate and durable efficacy, providing new treatment hope for severely refractory patients.

At present, teritusumab has been approved for marketing in China, but it has not yet been included in the medical insurance catalog. Since the drug is an imported innovative biological preparation, its price is relatively high. The foreign original version (such as 153mg/1.7ml specifications) costs about more than 50,000 yuan per box, and is mainly aimed at patients with better economic conditions. As dual-antibody drugs gradually come into public view, their status in the treatment of hematological tumors is increasing day by day. It is expected that if they can be included in medical insurance in the future, the accessibility and utilization rate of domestic patients will be significantly improved.

Reference materials:https://www.drugs.com/